JP Morgan Chase
SLNO

JP Morgan Chase’s Soleno Therapeutics SLNO Stock Holding History

JP Morgan Chase’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-156,800
Closed -$11.2M – 7590
2025
Q1 		$11.2M Buy
156,800
+155,800
+15,580% +$7.59M ﹤0.01% 2436
2024
Q4 		$45K Buy
+1,000
New +$51.8K ﹤0.01% 6053

JP Morgan Chase's SLNO Position: Q2 2026 in Review

JP Morgan Chase sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 51,480 shares — an estimated $1.57M sold.

JP Morgan Chase first reported a position in SLNO in Q4 2017 and held it in 25 quarters. The position peaked at $27.5M in Q3 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

  • JP Morgan Chase reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
  • JP Morgan Chase sold 51,480 Soleno Therapeutics shares in Q2 2026, an estimated $1.57M.
  • JP Morgan Chase first reported a position in Soleno Therapeutics in Q4 2017 and held it in 25 quarters.
  • JP Morgan Chase's Soleno Therapeutics position peaked at $27.5M in Q3 2025.
  • 0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.